Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746496 | 0.90 | GRIN2B (0.44) | SCN4APOLBGRIN2BDRD2DRD3 | |
| SCHEMBL13196697 | 0.88 | JAK2 (0.42) | SCN4APOLBGRIN2B | |
| SCHEMBL2799706 | 0.83 | HTR4 (0.35) | SCN4AGRIN2BDRD4KMT2A | |
| SCHEMBL2798097 | 0.83 | HTR4 (0.35) | SCN4AGRIN2BDRD4KMT2A | |
| SCHEMBL6310196 | 0.81 | CACNA1G (0.44) | POLBGRIN2BSIGMAR1S1PR1S1PR5 | |
| SCHEMBL2800688 | 0.80 | SIGMAR1 (0.45) | GRIN2BDRD2DRD4BCHESIGMAR1 | |
| SCHEMBL13201176 | 0.79 | TACR1 (0.47) | SIGMAR1 | |
| SCHEMBL2802478 | 0.79 | TACR1 (0.47) | SIGMAR1 | |
| SCHEMBL5746618 | 0.79 | HSD11B1 (0.46) | SCN4APOLBGRIN2BDRD2DRD3 | |
| SCHEMBL5746448 | 0.78 | DRD2 (0.44) | POLBGRIN2BDRD2DRD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | BAO JIANMING | 2010-08-05 | — | — | US | disclosed |
| EP-2170064-A1 | 6.5-PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009002770-A1 | 6.5-PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, TACR2, HTR1D | SCN4A 1770/4885POLB 4131/4885GRIN2B 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.